ИНГИБИТОРЫ SGLT2: ОБОСНОВАНИЕ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ПРИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

сердечная недостаточность, сахарный диабет, ингибиторы SGLT2, глифлозины, heart failure, diabetes, SGLT2 inhibitors, glyflozines

1. Maggioni A. P. Epidemiology of Heart Failure in Europe. Heart Fail Clin 2015;11 (4):625-635.

2. Ponikowski P., Voors A. A., Anker S. D. et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37 (27):2129-2200.

3. Fomin I. V. Epidemiology of chronic heart failure in Russian Federation. In: Ageev F. T., G. P. Arutyunov, Yu. N. Belenkov, Yu. A. Vasyuk, V. Yu. Mareev, A. V. Martynenko, M. Yu. Sitnikova, I. V. Fomin, E. V. Shlyakhto. Chronic heart failure. Geotar-Media, Moscow, 2010;7-77.

4. Crespo-Leiro M. G., Anker S. D., Maggioni A. P. et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18 (6):613-625.

5. Metra M., Teerlink J. R. Heart failure. Lancet 2017;390 (10106):1981-1995.

6. Chatterjee S., Khunti K., Davies M.J. Type 2 diabetes. Lancet 2017;389 (10085):2239-2251.

7. MacDonald M. R., Petrie M. C., Hawkins N. M. et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29 (10):1224-1240.

8. Targher G., Dauriz M., Laroche C. et al. ESC-HFA HF Long-Term Registry Investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:54-65.

9. Dei Cas A., Fonarow G. C., Gheorghiade M., Butler J. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol 2015;40:7-43.

10. Kannel W. B., Hjortland M., Castelli W. P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.

11. Dinesh Shah A., Langenberg C., Rapsomaniki E. et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1,9 million people. Lancet 2015;385 Suppl 1: S86.

12. Lehrke M., Marx N. Diabetes Mellitus and Heart Failure. Am J Med 2017;130 (6S): S40 - S50.

13. MacDonald M. R., Petrie M. C., Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-1385.

14. Johansson I., Dahlström U., Edner M. et al. Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. J Am Coll Cardiol 2016;68 (13):1404-1416.

15. Cubbon R. M., Adams B., Rajwani A. et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 2013; 10 (4):330-336.

16. Seferovic P. M., Paulus W.J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36 (27):1718-27,1727a-1727c.

17. Gilbert R. E., Krum H. Heart failure in diabetes: effects of antihyperglycaemic drug therapy. Lancet 2015;385 (9982):2107-2117.

18. Tomova G. S., Nimbal V., Horwich T. B. Relation between hemoglobin a (1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol 2012;109:1767-1773.

19. Turnbull F. M., Abraira C., Anderson R.J. et al., and the Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298.

20. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials. BMJ 2011;343: d4169.

21. Home P. D., Pocock S.J., Beck-Nielsen H. et al., RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.

22. DormandyJ. A., Charbonnel B., Eckland D.J. et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.

23. http://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM071627.pdf? utm_campaign=Google2utm_source=fdaSearchutm_ medium= websit-eutm_term=guidance

24. Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385 (9982):2067-2076.

25. Scirica B. M., Bhatt D. L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.

26. Biryukova E. V. Empagliflozin: increasing possibilities in treatment of type 2 diabetes mellitus. Farmateka 2016;318 (5):51-61. Russian (Бирюкова Е. В. Эмпаглифлозин: расширение возможностей терапии сахарного диабета 2-го типа. Фарматека 2016;318 (5):51-61.)

27. Wright E. M., Loo D. D., Hirayama B. A. Biology of human sodium glucose transporters. Physiol Rev 2011;91 (2):733-794.

28. Santer R., Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5 (1):133-141.

29. Ehrenkranz J. R., Lewis N. G., Kahn C. R., Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21 (1):31-38.

30. Tahrani A. A., Barnett A. H., Bailey C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1 (2):140-151.

31. Berhan A., Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 2013;13:58.

32. Sarashina A., Koiwai K., Seman L.J. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2013;28 (3):213-219.

33. Andrianesis V., Glykofridi S., Doupis J. The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab 2016;7 (5-6):212-228.

34. Scheen A.J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014;53 (3):213-225.

35. Krivosheeva A. A. The effects of sodium-glucose cotransporter 2 inhibotors on the effectiveness of type 2 diabetes mellitus management. Endocrinology: news, opinion, education 2017;19 (2):120-121.

36. Whalen K., Miller S., Onge E. S. et al. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 2015;37:1150-1166.

37. Shyangdan D. S., Uthman O. A., Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. BMJ Open 2016;6: e009417.

38. Merovci A., Solis-Herrera C., Daniele G. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124 (2):509-514.

39. Cherney D. Z., Perkins B. A., Soleymanlou N. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.

40. Zinman B., Wanner C., Lachin J. M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.

41. Fitchett D., Zinman B., Wanner C. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial. Eur Heart J 2016;37:1526-1534.

42. Fitchett D., Butler J., van de Borne P. et al.; EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2017 Aug 28. doi: 10.1093/eurheartj/ehx511. [Epub ahead of print]

43. Neal B., Perkovic V., de Zeeuw D. et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo-controlled trial. Am Heart J 2013;166 (2):217-223. e11.

44. Niessner A., Tamargo J., Koller L. et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2017 Nov 8. doi: 10.1093/eurheartj/ehx625. [Epub ahead of print]

45. Leiter LA, Cefalu WT, de Bruin TW et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab 2016;18 (8):766-74.

46. Cinti F., Moffa S., Impronta F. et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther 2017;11:2905-2919.

47. Kosiborod M., Cavender M. A., Fu A. Z. et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 2017;136 (3):249-259.

48. Ametov A. S., Kamynina L. L., Litvinenko V. M. Cardiovascular effects of SGLT2 inhibitors in type diabetes patients in real clinical practice: CVD-REAL study. Endocrinology: news, opinions, education 2017; 19 (2):28-36.

49. Patel A., Billot L. Reality and Truth: Balancing the Hope and the Hype of Real-World Evidence. Circulation 2017;136 (3):260-262.

50. Udell J. A., Yuan Z., Rush T. et al. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study. Circulation 2017 Nov 13. pii: CIRCULATIONAHA. 117.031227. doi: 10.1161/CIRCULATIONAHA. 117.031227. [Epub ahead of print]

51. Barnett A. H., Mithal A., Manassie J. et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2 (5):369-384.

52. Vallon V., Gerasimova M., Rose M. A. et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306 (2):F194-204.

53. Gilbert R. E. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 2014;86:693-700.

54. Wanner C., Inzucchi S. E., Lachin J. M. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.

55. Wanner C., Lachin J.M., Inzucchi S.E. et al.; EMPA-REG OUTCOME® investigators. Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease. Circulation 2017 Sep 13. pii: CIRCULATIONAHA. 117.028268. doi: 10.1161 /CIRCULATIONAHA. 117.028268. [Epub ahead of print]

56. Neal B., Perkovic V., Mahaffey K. W. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377 (7):644-657.

57. Neeland I.J., McGuire D. K., Chilton R. et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res 2016;13:119-126.

58. Sattar N., Petrie M. C., Zinman B., Januzzi J. L. Jr. Novel Diabetes Drugs and the Cardiovascular Specialist. J Am Coll Cardiol 2017;69 (21):2646-2656.

59. Terasaki M., Hiromura M., Mori Y. et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLOS ONE 2015;10: e0143396.

60. Rajeev S. P., Cuthbertson D.J., Wilding J. P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab 2016;18:125-134.

61. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPAREG OUTCOME trial: a «thrifty substrate» hypothesis. Diabetes Care 2016;39 (7):1108-1114.

62. Chong C. R., Clarke K., Levelt E. Metabolic Remodeling in Diabetic Cardiomyopathy. Cardiovasc Res 2017 Feb 8. doi: 10.1093/cvr/cvx018. [Epub ahead of print]

63. Wende A. R., Abel D. E. Lipotoxicity in the heart. Biochim Biophys Acta 2009;1801:311-319.

64. Chamberlain J.J., Herman W. H., Leal S. et al. Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 2017;166 (8):572-578.

65. Lytvyn Y., Skrtic M., Yang G. K. et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015;308: F77-F83.

66. Abdul-Ghani M., Del Prato S., Chilton R., DeFronzo R. A. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPAREG OUTCOME study. Diabetes Care 2016;39:717-725.

67. Marx N., McGuire D. K. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016;37 (42):3192-3200.

68. Korbut A. I., Klimontov V. V. Empagliflozin: new strategy of nephroprotection in diabetes mellitus. Diabetes mellitus 2017;20 (1):75-

69. Verbrugge F. H., Vangoitsenhoven R., Mullens W. et al. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes? Curr Cardiovasc Risk Rep 2015;9:38.

70. Baker W. L., Smyth L. R., Riche D. M. et al. Effects of sodium-glucose cotransporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8 (4):262-275.

71. Heerspink H.J., Perkins B. A., Fitchett D. H. et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752-772.

72. Sha S., Polidori D., Heise T. et al. Effect of the sodium glucose cotransporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16 (11):1087-1095.

73. Tikkanen I., Narko K., Zeller C. et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015;38 (3):420-428.

74. Martens P., Mathieu C., Verbrugge F. H. Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Curr Treat Options Cardiovasc Med 2017;19 (3):23.

75. Lambers Heerspink H.J., de Zeeuw D., Wie L. et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15 (9):853-862.

76. Butler J., Hamo C. E., Filippatos G. et al.; EMPEROR Trials Program. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fai. 2017 Nov;19 (11):1390-1400.

77. Baker W. L., Smyth L. R., Riche D. M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-275.

78. Chilton R., Tikkanen I., Cannon C. P. et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:1180-1193.

79. Verma S., Garg A., Yan A. T. et al. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care 2016;39 (12):e212 - e213.

80. Di Franco A., Cantini G., Tani A. et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol 2017;243:86-90.

81. Byrne N.J., Parajuli N., Levasseur J. L. et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. J Am Coll Cardiol Basic Trans Science 2017;2:347-354.

82. Baartscheer A., Schumacher C. A., Wüst R. C. et al. Empagliflozin decreases myocardial cytoplasmic Na^ through inhibition of the cardiac Na^/H^ exchanger in rats and rabbits. Diabetologia 2017;60:568-573.

83. Bertero E., Prates Roma L., Ameri P., Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res 2017 Aug 4. doi:10.1093/cvr/cvx149. [Epub ahead of print]

84. Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation 2017;136 (16):1548-1559.

85. Januzzi J. L. Jr, Butler J., Jarolim P. et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. J Am Coll Cardiol 2017;70 (6):704-712.

86. Wu J. H., Foote C., Blomster J., Toyama T. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review andmeta-analysis. Lancet Diabetes Endocrinol 2016;4 (5):411-419.

87. Zaccardi F., Webb D. R., Htike Z. Z. et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 2016;18:783-794.

88. Sonesson C., Johansson P. A., Johnsson E., Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016;15:37.

89. Vasilakou D., Karagiannis T., Athanasiadou E. et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2013;159:262-274.

90. Toto R. D., Wanner C., Gerich J. et al. No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol 2013;24 (Suppl.).

91. Rosenstock J., Ferrannini E., Peters A. et al. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642.

92. Bolinder J., Ljunggren O., Johansson L. et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159-169.

93. Ptaszynska A., Johnsson K. M., Parikh S.J. et al. Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events. Drug Saf 2014;37:815-829.

94. Cherney D. Z., Udell J. A. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. Circulation 2016;134 (24):1915-1917.

95. Piepoli M. F., Hoes A. W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2016;37 (29):2315-2381.

96. Ponikowski P., Voors A. A., Anker S. D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2129-2200.

97. Amosova M. V., Fadeev V. V. Empagliflozin - new indication for use - a turning point in treatment of type 2 diabetes mellitus. Meditsinskiy Sovet 2017;3:38-43.

98. Dedov I. I., Shestakova M. V., Mayorov A. Yu. et al. Clinical guidelines: Algorithms of specialized medical care of patients with diabetes mellitus (8th edition). Diabetes Mellitus 2017;20 (1S): 1-112

99. Demidova T. Yu., Salukhov V. V. Empagliflosin: new era in type 2 diabetes treatment. Terapiia 2016;4:6-16

100. Cariou B., Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs 2015;24 (12):1647-1656.

101. Marso S. P., Daniels G. H., Brown-Frandsen K. et al. Liraglutide and cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375 (4):311-322.

102. Marso S. P., Bain S. C., Consoli A. et al. Semaglutide and Cardiovascular outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375 (19):1834-1844.

103. Tanaka A., Node K. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol 2017;69 (3):501-507.

104. Pfeffer M. A., Claggett B., Diaz R. et al., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257.

105. Shestakova M. V., Sukhareva O. Yu. Gliflozins: Characteristics of glucose-lowering action and non-glycemic effects of new drug class. Clinical pharmacology and therapy 2016;2:65-71.

106. Jorsal A., Kistorp C., Holmager P. et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) -a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69-77.

107. Lytvyn Y., Bjornstad P., Udell J. A. et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017;136 (17):1643-1658.

108. Ahmed-Sarwar N., Nagel A. K., Leistman S., Heacock K. SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management? Ann Pharmacother 2017 Sep;51 (9):791-796.